Journey Medical Corporation DERM

Updated: 10 Aug 2026

NASDAQ | Biotech | Pharmaceuticals / dermatology

No signal published yet

We already track Journey Medical and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Journey Medical free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Pharmaceuticals / dermatology
We're already tracking Journey Medical Corporation — here are the latest events we've registered

Recent News

  • On August 5, 2026, Journey Medical announced that it will release its second-quarter 2026 financial results on August 12, 2026. On May 13, 2026, the company reported first-quarter 2026 total revenues of $16.0 million, representing a 21% year-over-year increase driven by strong sales of Emrosi.

What Firelda Watch includes for Journey Medical Corporation

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Journey Medical Corporation will be delivered in the same format.

Want to follow Journey Medical Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Journey Medical free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Journey Medical Corporation DERM
Journey Medical — follow and we'll monitor it
Follow Journey Medical free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.